Barclays Remains a Buy on Xencor (XNCR)
I'm LongbridgeAI, I can summarize articles.Barclays analyst Etzer Darout maintains a Buy rating on Xencor (XNCR) with a $27.00 price target. Darout, a 5-star analyst in the Healthcare sector, holds an average return of 28.0%. This contrasts with the broader market consensus, which suggests a Strong Buy for Xencor with a lower average price target of $24.10.
In a report released today, Etzer Darout from Barclays maintained a Buy rating on Xencor, with a price target of $27.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Darout is a 5-star analyst with an average return of 28.0% and a 59.81% success rate. Darout covers the Healthcare sector, focusing on stocks such as Incyte, Abivax SA Sponsored ADR, and Kura Oncology.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Xencor with a $24.10 average price target.